Patent Application
20090042209
The field of this invention is the area of protein biochemistry, in particular, as related to the diagnosis of neoplastic and diseased cells, as specifically related to particular isoforms of a cell surface marker characteristic of neoplasia in general and with specific patterns of protein expression indicative of specific types of cancer. Detection of the particular isoforms is by use of specific antibodies.
There is a unique, growth-related family of cell surface hydroquinone or NADH oxidases with protein disulfide-thiol interchange activity referred to as ECTO-NOX proteins (for cell surface NADH oxidases) (1,2). One member of the ECTO-NOX family, designated tNOX (for tumor associated) is specific to the surfaces of cancer cells and the sera of cancer patients (3, 4). The presence of the tNOX protein has been demonstrated for several human tumor tissues (mammary carcinoma, prostate cancer, neuroblastoma, colon carcinoma and melanoma) (5), and serum analysis suggest a much broader association with human cancer (6, 7).
NOX proteins are ectoproteins anchored in the outer leaflet of the plasma membrane (8). As is characteristic of other examples of ectoproteins (sialyl and galactosyl transferase, dipeptidylamino peptidase IV, etc.), the NOX proteins are shed. They appear in soluble form in conditioned media of cultured cells (5) and in patient sera (6, 7). The serum form of tNOX from cancer patients exhibits the same degree of drug responsiveness as does the membrane-associated form. Drug-responsive tNOX activities are seen in sera of a variety of human cancer patients, including patients with leukemia, lymphomas or solid tumors (prostate, breast, colon, lung, pancreas, ovarian, liver) (6, 7). An extreme stability and protease resistance of the tNOX protein (9) may help explain its ability to accumulate in sera of cancer patients to readily detectable levels. In contrast, no drug-responsive NOX activities have been found in the sera of healthy volunteers (6, 7) or in the sera of patients with disorders other than neoplasia.
While the basis for the cancer specificity of cell surface tNOX has not been determined, the concept is strongly supported by several lines of evidence. A drug responsive tNOX activity has been rigorously determined to be absent from plasma membranes of non-transformed human and animal cells and tissues (3). The tNOX proteins lack a transmembrane binding domain (10) and are released from the cell surface by brief treatment at low pH (9). A drug-responsive tNOX activity has not been detected in sera from healthy volunteers or patients with diseases other than cancer (6, 7). Several tNOX antisera have identified the immunoreactive band at 34kDa (the processed molecular weight of one of the cell surface forms of tNOX) with Western blot analysis or immunoprecipitation when using transformed cells and tissues or sera of cancer patients as antigen source (5,10,11). The immunoreactive band at 34kDa is absent with western blot analysis or immunoprecipitation when using transformed cells and tissues or sera from healthy volunteers or patents with disorders other than cancer (5,10,11). These antisera include a monoclonal antibody (5), single-chain variable region fragment (scFv) which reacts with the cell surface NADH oxidase from normal and neoplastic cells, polyclonal antisera made in response to expressed tNOX (11) and polyclonal peptide antisera to the conserved adenine nucleotide binding region of tNOX (11).
tNOX cDNA has been cloned (GenBank Accession No. AF207881; 11; U.S. Patent Publication 2003-0207340 A1). The derived molecular weight from the open reading frame was 70.1 kDa. Functional motifs include a quinone binding site, an adenine nucleotide binding site, and a CXXXXC cysteine pair as a potential protein disulfide-thiol interchange site based on site-directed mutagenesis (11). Based on available genomic information (12) the tNOX gene is located on chromosome X, and it is comprised of multiple exons (thirteen). It is known that there are a number of splice variant mRNAs and proteins expressed.
The hybridoma cell line which produces the tumor NADH oxidase-specific monoclonal antibody MAB 12.1 was deposited with the American Type Culture Collection, Manassas, Va., 20108 on Apr. 4, 2002, under the terms of the Budapest Treaty. This deposit is identified by Accession No. ATCC PTA-4206. The deposit will be maintained with restriction in the ATCC depository for a period of 30 years from the deposit date, or 5 years after the most recent request, or for the effective life of the patent, which ever is longer, and will be replaced if the deposit becomes non-viable during that period. This monoclonal antibody is described in U.S. Pat. No. 7,053,188, issued May 30, 2006, which is incorporated by reference herein.
Because cancer poses a significant threat to human health and because cancer results in significant economic costs, there is a long-felt need in the art for an effective, economical and technically simple system in which to assay for the presence of cancer.
The present invention provides a method for the analysis of a biological sample for the presence of particular isoforms of the pan-cancer antigen known as tNOX (for tumor-specific NADH oxidase). The present method entails 2-dimensional gel electrophoresis and immunoblotting using an antibody specific for the pan-cancer tNOX antigen and the various isoforms which characterize particular types of cancers. As specifically exemplified, about 4-6 mg protein are loaded for analysis.
The present invention provides a method for the detection of particular cancer-specific serum or plasma tNOX isoforms as indicators of the presence of cancer and of the cell type or tissue of cancer origin (breast, ovarian prostate, etc). tNOX isoforms are identified on the basis of their molecular mass and isoelectric point with detection using a tNOX-specific monoclonal antibody (MAB) (U.S. Pat. No. US 7,053,188), using single chain variable region (ScFv) fragment which recognizes all cell surface NOX proteins (both age-related, normal cell and neoplasia specific NADH oxidase) or using polyclonal sera raised against tNOX. The ECTO-NOX proteins are first enriched and concentrated from a biological sample, desirably a serum sample, by binding to nickel-agarose and then eluting. After release of the proteins from the nickel-agarose by vortexing, the proteins are separated in the first dimension by isoelectric focusing and in the second dimension by polyacrylamide gel electrophoresis. As specifically exemplified herein, the isoelectric focusing step is over a pH range from 3 to 10, and size separation is over a 10% polyacrylamide gel. Most of the cancer-specific tNOX isoforms exhibit isoelectric points in a very narrow range between pH 4.4 and 5.4 but differ in molecular weight from 34 to 136 kDa. In the 2D gel system specifically exemplified, the cancer-specific isoforms are located in Quadrants I (relatively high molecular weight material) and IV (lower molecular weight material, notably the 34 and 43 kDa isoforms). IgG heavy chains (Quadrant II and IgG light chains (Quadrant III) cross react with the ScFv antibody and serve as loading controls. The absence of all tNOX isoforms indicates the absence of cancer; the presence of a tNOX isoform indicates the presence of cancer. The particular molecular weight present in a serum sample or a particular combination of isoforms provides an indication of the cell type or tissue of origin of the cancer. The method not only determines cancer presence, but also the method of the present invention provides diagnostic information concerning the tissue of origin. At present there are no other pan cancer (all forms of human cancer) tests with these particular capabilities.
The present invention provides a method for determining neoplasia in a mammal, including a human, said method comprising the steps of detecting cancer presence, in a biological sample. The present invention further provides additional information for assessment of neoplasia, including a measure of tumor burden, for example in serum, plasma, urine, saliva or in biopsy material.
Also within the scope of the present invention are particular isoforms of tNOX associated with specific (primary) cancers: tNOX proteins with apparent molecular weights of about 64, 66 and/or 68 kDa are associated with breast cancer; two tNOX proteins of about 40.5 and 52 kDa are associated with small cell lung cancer; tNOX proteins of about 40.5, 52 and 80 kDa characterize ovarian cancer; two tNOX isoforms of about 75 kDa designated 75α and 75β are associated with prostate cancer; a tNOX protein of about 94 kDa is associated with cervical cancer; tNOX proteins of about 43 and 52 kDa are characteristic of colon cancer; and a tNOX isoform of about 54 kDa is associated with non small cell lung cancer. Where a patient is suspected of having cancer, a biological sample, advantageously a serum sample can be prepared, and the 2D gel electrophoresis/immunological analysis of the present invention can be undertaken. Positive results are indicative of the presence of cancer, and the detection of characteristic proteins allow a presumption as to the primary incidence of cancer in that patient according to the association of particular protein(s) with particular cancer origins, as set forth above.
The methods of the present invention can also be applied to evaluate response to therapy, with decreasing amounts of NOX isoform(s) reflecting successful treatment, as well as early detection of recurrent disease (reflected increased or reappearance of tNOX-specific isoforms.
The cancer diagnostic system of the present invention utilizes two-dimensional polyacrylamide gel electrophoretic techniques for the separation of proteins in human sera to generate cancer-specific isoform patterns and compositions indicative of cancer presence, tumor type, disease severity and therapeutic response. The protocol is designed for the detection of at least 20 cancer-specific tNOX isoforms which are resolved to indicate cancer presence and disease severity. This specification illustrates the process of the isoform-resolving two-dimensional gel electrophoresis protocol and subsequent immunoanalysis to detect tNOX isoforms which reflect particular cancers.
Two-dimensional gel electrophoresis separates by displacement in two dimensions oriented at right angles to one another and immunoblotting identifies the tNOX isoforms. In the first dimension isoforms are separated according to charge (pI) by isoelectric focusing (IEF). The isoforms are then separated according to size (Mr) by SDS-PAGE in a second dimension. The isoforms are then blotted onto a nitrocellulose membrane for further analysis using a pan-cancer specific antibody preparation.
Rabbits were immunized and sera were prepared against a 33.5 kDa component of culture medium conditioned by the growth of HeLa cells that exhibited an antitumor sulfonylurea-(Morré et al. (1995) Biochim. Biophys. Acta 1240:11-17) and capsaicin-inhibited (Morré et al. (1995) Proc. Natl. Acad. Sci. USA 92:1831-1835) NADH oxidase activity and was capable of binding (3H)-LY181984. These antisera cross-reacted on Western blots with the 34 kDa tNOX protein from HeLa cells and with the 68 kDa and 136 kDa multimeric bands of the material from FPLC separations enriched in capsaicin-inhibitable NADH oxidase activity. No reactivity was observed with preimmune sera.
Antibodies specific for the plasma membrane tNOX and the shed forms in urine and serum of cancer patients and animals with neoplastic disorders are useful, for example, as probes for screening DNA expression libraries or for detecting or diagnosing a neoplastic disorder in a sample from a human or animal. The antibodies (or second antibodies which are specific for the antibody which recognizes tNOX) can be bound to a substance which provides a cofactor, inhibitor, fluorescent agent, chemiluminescent agent, magnetic particle or other detectable signal. Suitable labels include but are not limited to radionuclides, enzymes, substrates, magnetic particles and the like. United States Patents describing the use of such detectable moieties (labels) include, but are not limited to, U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; 4,331,647; 4,348,376; 4,361,544; 5,444,744; 4,460,561; 4,624,846; 4,366,241, 5,716,595; among others. For use in therapeutic regimens, the antibody of the present invention can be coupled to a therapeutic radionuclide, a chemotherapeutic agent, a ribonucleolytic agent or a toxin. See, among others, U.S. Pat. Nos. 5,541,297, 6,395,276.The invention may be further understood by the following non-limiting examples.
Sample preparation is carried out as follows.
Serum tNOX Protein Concentration and Enrichment
1. Centrifuge tubes (above) at 1,000 g for 30 seconds
2. Discard supernatant
3. Wash beads 3x with deionized distilled-H20 as described above
First-Dimension (Isoelectric focusing, IEF) is carried out as follows.
1. Prepare/thaw re-hydration solution
2. Add 150 μl of re-hydration solution to agarose bound sample
3. Vortex tubes for 75 minutes
4. Remove Immobiline DryStrips (Amersham Pharmacia Biotech) from freezer and allow strips to equilibrate to room temperature for 5 minutes (but not more than 10 min prior to use).
Alternative Sample Preparation.
Isoelectric Focusing of Strips
Second-Dimension (SDS-PAGE) is carried out as follows.
Preparation of the SDS-PAGE Gel
Equilibration of IEF Strips
Loading and Running Second-Dimension Gel
Agarose must be cool enough to not disrupt marker
Transferring Proteins
Silver staining to visualize total protein (optional).
Immunological analysis of the blot is carried out as follows.
Solutions used in the foregoing protocols are given below.
Formulations for Protean II gels (20×20; 1-mm thick)
NOX-Enriched serum proteins (approximately 4-6 mg) from sera pooled from cancer patients (breast, ovarian, lung and colon) were resolved by 2-D gel electrophoresis with detection by recombinant anti-ECTO-NOX antibody (single chain variable region ScFv) carrying an S-tag followed by alkaline phosphatase-linked anti-S with Western Blue NBT alkaline phosphatase substrate yield several proteins present in the cancer sera (
Where sera specific for tNOX or ECTO-NOX are used, typically the dilution is from 1:10 to 1:1000, monoclonal antibody (e.g., 12.1 produced by hybridoma on deposit as ATCC Accession No. PTA-4206) is from 1 ;100-1:10,00, desirably about 1:100, or ascites fluid from growth of the same hybridoma can be from about 1:10 to about 1:1000, desirably about 1:100.
Results combined from a total of eight different pooled cancer sera were similar to those of
2-D gel analysis as in
2-D gel analysis as in
2-D gel analysis as in
2-D gel analysis as in
2-D gel analysis as in
2-D gel analysis as in
2-D gel analysis as in
For each kind of cancer there appears to be a tNOX isoform (ovarian, breast, cervical, colon, non-small cell lung, prostate small cell lung) or combination of tNOX isoforms that is specific to the tissue or cell type of origin for the cancer (
The 2-D gel of
In more than 25 randomly selected outpatient sera and sera of healthy volunteers, both quadrants I and IV of the 2-D gels were devoid of tNOX isoforms (FIG. 12), confirming previous observations that tNOX proteins are absent from non-cancer patients or sera of healthy volunteers.
The diagnostic strategy of the invention combines one- and two-dimensional polyacrylamide gel electrophoretic separations of human sera to generate cancer specific isoform patterns and compositions indicative of cancer presence, tumor type, disease severity and therapeutic response. At least 20 cancer-specific tNOX isoforms are resolved indicative of cancer presence and disease severity. The system consists of a concentration step where ECTO-NOX proteins are separated from the bulk of the albumin and other serum proteins using a nickel-agarose precipitation. Detection uses a recombinant single chain antibody (scFv) that cross reacts with all known ECTO-NOX isoforms of human origin; this antibody also has an S-tag that reacts with a second antibody I (anti-S). The scFv antibody is described in U.S. Provisional Application 60/824,398, filed Sep. 1, 2006 and below.
Monoclonal antibody generated against tNOX NADH oxidase tumor cell specific was produced in sp-2 myeloma cells; however, the monoclonal antibody slowed the growth of sp-2 myeloma cells that were used for fusion with spleen cells after 72 h. This phenomenon made it difficult to produce antibody in quantity. To overcome this problem, the coding sequences of the antigen-binding variable region of the heavy chain and the light chain (Fv region) of the antibody cDNA were cloned and linked into one chimeric gene, upstream of the S-tag coding sequence. The Fv portion of an antibody, consisting of variable heavy (VH) and variable light (VL) domains, can maintain the binding specificity and affinity of the original antibody (Glockshuber et al. 1990. Biochemistry 29:1262-1367).
For a recombinant antibody, cDNAs encoding the variable regions of immunoglobulin heavy chain (VH) and light chain (VI), are cloned by using degenerative primers. Mammalian immunoglobulins of light and heavy chain contain conserved regions adjacent to the hypervariable complementary defining regions (CDRs). Degenerate oligoprimer sets allow these regions to be amplified using PCR (Jones et al. 1991. BiolTechnology 9:88-89; Daugherty et al. 1991. Nucleic Acids Research 19:2471-2476). Recombinant DNA techniques have facilitated the stabilization of variable fragments by covalently linking the two fragments by a polypeptide linker (Huston et al. 1988. Proc. Natl. Acad. Sci. USA 85:5879-5883). Either VL or VH can provide the NH2-terminal domain of the single chain variable fragment (ScFv). The linker should be designed to resist proteolysis and to minimize protein aggregation. Linker length and sequences contribute and control flexibility and interaction with ScFv and antigen. The most widely used linkers have sequences consisting of glycine (Gly) and serine (Ser) residues for flexibility, with charged residues as glutamic acid (Glu) and lysine (Lys) for solubility (Bird et al. 1988. Science 242:423-426; Huston et al. 1988. supra).
Total RNA was isolated from the hybridoma cells producing tNOX-specific monoclonal antibodies by the following procedure modified from Chomczynski et al. (1987) Anal. Biochem. 162:156-159 and Gough (1988) Anal. Biochem 176:93-95. Cells were harvested from medium and pelleted by centrifugation at 450× g for 10 min. Pellets were gently resuspended with 10 volumes of ice cold PBS and centrifuged again. The supernatant was discarded and cells were resuspended with an equal volume of PBS. Denaturing solution (0.36 ml of 2-mercaptoethanol/50 ml of guanidinium stock solution-4M guanidinium thiocyanate, 25 mM sodium citrate, pH 7.0, 0.5% sarkosyl) 10 ml per 1 g of cell pellet was added prior to use and mixed gently. Sodium acetate (pH 4.0,1 ml of 2M), 10 ml of phenol saturated water and 2 ml of chloroform: isoamyl alcohol (24:1) mixtures were sequentially added after each addition. The solution was mixed thoroughly by inversion. The solution was vigorously shaken for 10 sec, chilled on ice for 15 min and then centrifuged 12,000× g for 30 min. The supernatant was transferred and an equal volume of 2-propanol was added and placed at −20° C. overnight to precipitate the RNA. The RNA was pelleted for 15 min at 12,000× g, and the pellet was resuspended with 2-3ml of denaturing solution and 2 volumes of ethanol. The solution was placed at −20° C. for 2 h, and then centrifuged at 12,000× g for 15 min. The RNA pellet was washed with 70% ethanol and then 100% ethanol. The pellet was resuspended with RNase-free water (DEPC-treated water) after centrifugation at 12,000× g for 5 min. The amount of isolated RNA was measured spectrophotometrically and calculated from the absorbance at 280 nm and 260 nm.
The poly(A)mRNA isolation kit was purchased from Stratagene. Total RNA was applied to an oligo(dT) cellulose column after heating the total RNA at 65° C. for 5 min. Before applying, the RNA samples were mixed with 500 μl of 10× sample buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 5 M NaCl). The RNA samples were pushed through the column at a rate of 1 drop every 2 sec. The eluates were pooled and reapplied to the column and purified again. Preheated elution buffer (65° C.) was applied, and mRNA was eluted and collected in 1.5 ml of centrifuge tubes on ice. The amount of mRNA was determined at OD260 (1 OD unit=40 μg of RNA). The amounts of total RNA and mRNA obtained from 4×108 cells were 1328 μg and 28 μg, respectively.
mRNA (1-2 μg) dissolved in DEPC-treated water was used for cDNA synthesis. mRNA isolated on three different dates was pooled for first-strand cDNA synthesis. The cDNA synthesis kit was purchased from Pharmacia Biotech. mRNA (1.5 μg/5 μl of DEPC-treated water) was heated at 65° C. for 10 min. and cooled immediately on ice. The primed first strand mix containing MuLV reverse transcriptase (11 μl) and appropriate buffers for the reaction were mixed with mRNA sample. DTT solution (1 μl of 0.1 M) and RNase-free water (16 μl) also were added to the solution. The mixture was incubated for 1 h at 37° C.
Degenerate primers for light chain and heavy chain (Novagen, Madison, Wis.) were used for PCR. PCR synthesis was carried out in 100 μl reaction volumes in 0.5 ml microcentrifuge tubes by using Robocycler (Stratagene, La Jolla, Calif.). All PCR syntheses included 2 μl of sense and anti-sense primers (20 pmoles/μl), 1 μl of first-strand cDNA as a template, 2 μl of 10 mM of dNTPs, 1 μl of Vent polymerase (2 units/μl), 10 μl of 10×PCR buffer (100 mM Tris-HCl, pH 8.8 at 25° C., 500 mM KCl, 15 mM MgCl2, 1% Triton X-100), 82 μl of H2O. Triton X-100 is t-octylphenoxypolyethoxyethanol. All PCR profiles consisted of 1 min of denaturation at 94° C., 1 min of annealing at 55° C., and 1 min of extension at 72° C. This sequence was repeated 30 times with a 6-min extension at 72° C. in the final cycle. PCR products were purified with QIAEX II gel extraction kit from Qiagen, Valencia, Calif. PCR amplification products for heavy and light chain coding sequences were analyzed by agarose gel electrophoresis and were about 340 base pair (bp) long and 325 bp long, respectively.
Total RNA or DNA was analyzed by agarose gel electrophoresis (1% agarose gels). Agarose (0.5 g in 50 ml of TAE buffer, 40 mM Tris-acetate, 1 mM EDTA) was heated for 2 min in a microwave to melt and evenly disperse the agarose. The solution was cooled at room temperature, and ethidium bromide (0.5 μg/ml) was added and poured into the apparatus. Each sample was mixed with 6×gel loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF, 40% (w/v) sucrose in water). TAE buffer was used as the running buffer. Voltage (10 v/cm) was applied for 60-90 min.
According to the proper size for heavy and light chain cDNAs, the bands were excised from the gels under UV illumination, and excised gels were placed in 1 ml syringes fitted with 18-gauge needles. Gels were crushed to a 1.5 ml Eppendorf tube. The barrel of each syringe was washed with 200 μl of buffer-saturated phenol (pH 7.9±0.2). The mixture was thoroughly centrifuged and frozen at −70° C. for 10 min. The mixture was centrifuged for 5 min, and the top aqueous phase was transferred to a new tube. The aqueous phase was extracted again with phenol/chloroform (1:1). After centrifuging for 5 min, the top aqueous phase was transferred to a clean tube, and chloroform extraction was performed. Sodium acetate (10 volumes of 3 M) and 2.5 volumes of ice-cold ethanol were added to the top aqueous phase to precipitate DNA at −20° C. overnight.
Purified heavy and light chain cDNAs were ligated into plasmid pSTBlue-1 vector and transfected into NovaBlue competent cells (Stratagene). Colonies containing heavy and light chain DNAs were screened by blue and white colony selection and confirmed by PCR analysis. Heavy and light chain DNAs were isolated and sequenced using standard techniques. Tables 2A and 2B show the DNA sequences of heavy and light chain DNAs of ScFv. See also SEQ ID NO: 3 and SEQ ID NO: 4.
PCR amplification and the assembly of single ScFv gene was according to Davis et al. (1991) Bio/Technology9:165-169. Plasmid pSTBlue-1 carrying VH and VL genes were combined with all four oligonucleotide primers in a single PCR synthesis. Following first PCR synthesis, one tenth of the first PCR product was removed and added to a second PCR reaction mixture containing only the primer a (VH sense primer) and primer d (VL Antisense primer). The product of the second PCR synthesis yielded single ScFv gene. The single ScFv gene was ligated to plasmid pT-Adv (Clontech, Palo Alto, Calif.). pT-Adv carrying ScFv gene was used for DNA sequencing.
The complete ScFv gene was assembled from the VH, VL and linker genes to yield a single ScFv gene by PCR (Tables 2A and 2B). The DNA sequence encoding the linker was 45 nucleotides long (GGAGGCGGTGGATCGGGCGGTGGCGGCTCGGGTGGCGGCGGCTCT; SEQ ID NO:6), which translates to a peptide of 15 amino acids (GlyGlyGlyGlySerGlyGlyGlyGlySerGlyGlyGlyGlySer; SEQ ID NO:5). Primers for PCR amplification are shown in Tables 2A and 2B. S-peptide was linked to the C-terminus of ScFv[ScFv(S)]. S-peptide binds to S-protein conjugated to alkaline phosphatase for Western blot analysis. The DNA sequence of the S-peptide is AAAGAAACCGCTGCTGCTAAATTCGAACGCCAGCACATGGACAGC (SEQ ID N 0:7) which translates to S-peptide (LysGluThrAlaAlaAlaLysPheGluArgGlnHisMetAspSer; SEQ ID NO:8).
Recombinant ScFv(S) was expressed in E. coli. First, oligo nucleotides encoding S-peptide were linked to the 3′ end of the open reading frame (ORF) of ScFv DNA by PCR amplification. Incorporation of S-peptide enables to detect expressed ScFv protein by S-protein conjugated to alkaline phosphatase. The tNOX-specific ScFv(S) coding sequence was then subcloned to plasmid pET-11a, a plasmid designed for protein expression in E. coli (Stratagene, Calif.). For PCR amplification, two primers were designed to amplify ORF of ScFv(S) containing endonuclease restriction sites (Ndel and Nhel) and S-peptide residues. Plasmid pET-11a and ORF of ScFv(S) were digested with restriction enzymes Ndel and Nhel and ligated to produce plasmid pET11-ScFv(S). E. coli BL21 (DE3) was transformed with pET11-ScFv(S) and grown at 37° C. for 12 h in LB medium containing ampicillin (100 μg/ml). ScFv was expressed by addition of 0.5 mM IPTG and incubation for 4 h. Cells were harvested and lysed using a French Pressure Cell (French Pressure Cell Press, SLM Instruments, Inc.) (three passages at 20,000 psi). Cell extracts were centrifuged at 10,000×g for 20 min. Pellets containing denatured inclusion bodies of ScFv were collected. Renaturation of the inclusion bodies of the ScFv was according to Goldberg et al. (1995) Folding & Design 1:21-27.
ctgaaaatgt gctcacccag tctccagcaa tcatgtctgc atctccaggg
cgccagcaca tggacagc s-peptide
RQHMDS s-peptide
Standard techniques for cloning, DNA isolation, amplification and purification, for enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like, and various separation techniques are those known and commonly employed by those skilled in the art. A number of standard techniques are described in Sambrook et al. (1989) Molecular Cloning, Second Edition, Cold Spring Harbor Laboratory, Plainview, N.Y.; Maniatis et al. (1982) Molecular Cloning, Cold Spring Harbor Laboratory, Plainview, N.Y.; Wu (ed.) (1993) Meth. Enzymol. 218, Part I; Wu (ed.) (1979) Meth. Enzymol. 68; Wu et al. (eds.) (1983) Meth. Enzymol. 100 and 101; Grossman and Moldave (eds.) Meth. Enzymol. 65; Miller (ed.) (1972) Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.; Old and Primrose (1981) Principles of Gene Manipulation, University of California Press, Berkeley; Schleif and Wensink (1982) Practical Methods in Molecular Biology; Glover (ed.) (1985) DNA Cloning Vol. I and II, IRL Press, Oxford, UK; Hames and Higgins (eds.) (1985) Nucleic Acid Hybridization, IRL Press, Oxford, UK; Setlow and Hollaender (1979) Genetic Engineering: Principles and Methods, Vols. 1-4, Plenum Press, New York; Fitchen, et al. (1993) Annu. Rev. Microbiol. 47:739-764; Tolstoshev, et al. (1993) in Genomic Research in Molecular Medicine and Virology, Academic Press; and Ausubel et al. (1992) Current Protocols in Molecular Biology, Greene/Wiley, New York, N.Y. Abbreviations and nomenclature, where employed, are deemed standard in the field and commonly used in professional journals such as those cited herein. Antibody vaccines are described in Dillman R. O. (2001) Cancer Invest. 19(8):833-841. Durrant L. G. et al. (2001) Int J. Cancer 1;92(3):414-20 and Bhattacharya-Chatterjee M, (2001) Curr. Opin. Mol. Ther. Feb;3(1):63-9 describe anti-idiotype antibodies. Many of the procedures useful for practicing the present invention, whether or not described herein in detail, are well known to those skilled in the arts of molecular biology, biochemistry, immunology, and medicine.
Monoclonal, polyclonal antibodies, peptide-specific antibodies or single chain recombinant antibodies and antigen binding fragments of any of the foregoing, specifically reacting with the tNOX isoform proteins described herein, may be made by methods known in the art. See e.g., Harlow and Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratories; and Goding (1986) Monoclonal Antibodies: Principles and Practice, 2d ed., Academic Press, New York.
All references cited in the present application are incorporated by reference herein to the extent that there is no inconsistency with the present disclosure. Such references reflect the skill in the arts relevant to the present invention.
The examples provided herein are for illustrative purposes, and are not intended to limit the scope of the invention as claimed herein. Any variations in the exemplified antibodies, epitopes, purification methods, diagnostic methods, preventative methods, treatment methods, and other methods which occur to the skilled artisan are intended to fall within the scope of the present invention.
1. Morré, D. J. (1998) in Plasma Membrane Redox Systems and Their Role in Biological Stress and Disease (Asard, H., Bérczi, A. and Caubergs, R. J., Eds) pp.121-156, Kluwer Academic Publishers, Dordrecht, Netherlands.
2. Morré, D. J. and Morré, D. M. (2003) Free Radical Res. 37: 795-808
3. Morré, D. J., Chueh, P.-J. and Morré, D. M. (1995) Proc. Natl. Acad.
Sci. USA 92:1831-1835.
4. Bruno, M., Brightman, A. O., Lawrence, J., Werderitsh, D., Morré, D. M. and Morré, D. J. (1992) Biochem. J. 284: 625-628.
5. Cho, N., Chueh, P.-J., Kim, C., Caldwell, S., Morré, D. M. and Morré, D. J. (2002) Cancer Immunol. Immunother. 51: 121-129.
6. Morré, D. J., Caldwell, S., Mayorga, A., Wu, L-Y. and Morré, D. M. (1997) Arch. Biochem. Biophys. 342: 224-230.
7. Morré, D. J. and Reust, T. (1997) J. Bioenerg. Biomemb. 29, 281-289.
8. Morré, D. J. (1995) Biochim. Biophys. Acta 1240: 201-208.
9. del Castillo-Olivares, A., Chueh, P.-J., Wang, S., Sweeting, M., Yantiri, F., Sedlak, D., Morré, D. J. and Morré, D. M. (1998) Arch. Biochem. Biophys. 358: 125-140.
10. Morré, D. J., Sedlak, D., Tang, X., Chueh, P.J., Geng, T. and Morré, D. M. (2001) Arch. Biochem. Biophys. 392: 251-256.
11. Chueh, P. J., Kim, C., Cho, N., Morré, D. M. and Morré, D. J. (2002) Biochemistry 41: 3732-3741.
12. Bird, C. (1999) Direct submission of human DNA sequence from clone 875H3 (part of APK1 antigen) to GenBank database at NCBI. (Accession no. AL049733).
13. Braman, J., Papworth, C. and Greener, A. (1996) Methods Mol. Biol. 57: 31-44.
14. Wilkinson, F. E., Kim, C., Cho, N., Chueh, P.J., Leslie, S., Moya-Camerena, S., Wu, L.-Y., Morré, D. M. and Morré, D. J. (1996) Arch. Biochem. Biophys. 336: 275-282.
15. Morré, D. J., Wu, L.-Y. and Morré, D. M. (1995) Biochim. Biophys. Acta 1240: 11-17.
16. Morré, D. J., Kim, C., Paulik, M., Morré, D. M. and Faulk, W. P. (1997) J. Bioenerg. Biomembr 29: 269-280
17. Morré, D. J., Bridge, A., Wu, L.-Y. and Morré, D. M. (2000) Biochem. Pharmacol. 60: 937-946.
18. Kozak M. (1978) Cell. 15: 1109-23.
19. Kozak, M. (1989) J. Cell Biol. 108: 229-241.
20. Tatyana, V., Borukhov, S. I. and Hellen C. (1998) Nature 394: 854-859.
21. Van der Velden, A. W. and Thomas, A. A. (1999) Int. J. Biochem. Cell Biol. 31: 87-106.
22. Suzuki, Y., Ishihara, D., Sasaki, M. Nakagawa, H., Hata, H., Tsunoda, T., Wantanabe, M., Komatsu, T., Ota, T., Isogai. T., Suyama, A., and Sugano, S. (2000) Genomics 64: 286-297.
23. Kozak, M. (1987) Nucleic Acids Res. 15: 8125-8148.
This application claims benefit of U.S. Provisional Application 60/824,398 and U.S. Provisional Application 60/824,333, both filed Sep. 1, 2006, and both incorporated by reference herein to the extent there is no inconsistency with the present disclosure.
| Number | Date | Country | |
|---|---|---|---|
| 60824398 | Sep 2006 | US | |
| 60824333 | Sep 2006 | US |
